Market revenue in 2022 | USD 153.8 million |
Market revenue in 2030 | USD 293.9 million |
Growth rate | 8.4% (CAGR from 2022 to 2030) |
Largest segment | Reagents & consumables |
Fastest growing segment | Reagents & Consumables |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Analyzers, Reagents & Consumables |
Key market players worldwide | BioMerieux SA, Roche Holding AG, Siemens Healthineers AG ADR, Abbott Laboratories, Horiba Ltd, QuidelOrtho Corp, Thermo Fisher Scientific Inc, Biomedica Diagnostics, Werfen, Diazyme Laboratories |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to thrombosis and hemostasis biomarkers market will help companies and investors design strategic landscapes.
Reagents & consumables was the largest segment with a revenue share of 65.28% in 2022. Horizon Databook has segmented the South Korea thrombosis and hemostasis biomarkers market based on analyzers, reagents & consumables covering the revenue growth of each sub-segment from 2018 to 2030.
The key factors driving this market are the growing geriatric population, advancements in testing technologies for hemostasis & thrombosis, and the increasing prevalence of thrombotic disorders. The increasing demand for point-of-care testing devices is also a key factor contributing to the growth of the market.
For instance, as per the Population and Housing Census statistics published by Statistics Korea, more than 7.12 million people in South Korea are aged 65 years and above. Some of the major players in the country’s thrombosis and hemostasis biomarkers market are Siemens Healthcare, Bio-Rad-Laboratories, and F. Hoffman-LA Roche AG.
As per the Korean Biomedical Review-Journal, the South Korean biomarker technology market is still at a nascent stage, and the industry needs support from the government to develop further to meet the rising demand for personalized medicine in the country.
Horizon Databook provides a detailed overview of country-level data and insights on the South Korea thrombosis and hemostasis biomarkers market , including forecasts for subscribers. This country databook contains high-level insights into South Korea thrombosis and hemostasis biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account